Safe to use Belantamab Mafodotin for transplant-ineligible patients with newly diagnosed multiple myeloma
Current treatment regime for transplant-ineligible patients with newly diagnosed multiple myeloma is lenalidomide plus dexamethasone (Rd). Addition of Belantamab Mafodotinn (belamaf) has shown to lead to higher responses. In this MEDtalk Dr. Evangelos Terpos presents an open-label single center study investigating the safety profile of belamaf in three different treatment doses ranging between 1,4-2,5 mg/kg. Results suggest no new safety signals in the belamaf-Rd combination.